Page 3 - ESGO - Vulvar cancer - Complete report_fxd2

10.3 Development group comments ................................................................................................................................. 29
10.4 Guidelines................................................................................................................................................................. 29
11 Radiation therapy .................................................................................................................................................... 31
11.1 Summary of available scientific evidence................................................................................................................. 31
11.2 Previous initiatives.................................................................................................................................................... 32
11.3 Development group comments ................................................................................................................................. 33
11.4 Guidelines................................................................................................................................................................. 33
12 Chemoradiation ....................................................................................................................................................... 35
12.1 Summary of available scientific evidence................................................................................................................. 35
12.2 Previous initiatives.................................................................................................................................................... 37
12.3 Development group comments ................................................................................................................................. 37
12.4 Guidelines................................................................................................................................................................. 37
13 Systemic treatment .................................................................................................................................................. 43
13.1 Summary of available scientific evidence................................................................................................................. 43
13.2 Previous initiatives.................................................................................................................................................... 43
13.3 Development group comments ................................................................................................................................. 43
13.4 Guidelines................................................................................................................................................................. 43
14 Treatment of recurrent disease............................................................................................................................... 45
14.1 Summary of available scientific evidence................................................................................................................. 45
14.2 Previous initiatives.................................................................................................................................................... 45
14.3 Development group comments ................................................................................................................................. 45
14.4 Guidelines................................................................................................................................................................. 45
15 Follow-up.................................................................................................................................................................. 48
15.1 Summary of available scientific evidence................................................................................................................. 48
15.2 Previous initiatives.................................................................................................................................................... 48
15.3 Development group comments ................................................................................................................................. 48
15.4 Guidelines................................................................................................................................................................. 48
16 Acronyms and abbreviations .................................................................................................................................. 49
17 References................................................................................................................................................................. 51
18 Appendices ............................................................................................................................................................... 66
18.1 Appendix 1 - People involved in the development of the guidelines ........................................................................ 66
18.2 Appendix 2 - List of evidence-based medicine websites consulted .......................................................................... 73
18.3 Appendix 3 - Key to evidence statements and grades of recommendations.............................................................. 74

 VULVAR CANCER - GUIDELINES 
3